Annual SG&A:
$127.91M+$103.66M(+427.49%)Summary
- As of today, INBX annual SG&A is $127.91 million, with the most recent change of +$103.66 million (+427.49%) on December 31, 2024.
- During the last 3 years, INBX annual SG&A has risen by +$115.55 million (+935.25%).
- INBX annual SG&A is now at all-time high.
Performance
INBX SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly SG&A:
$5.28M-$1.15M(-17.83%)Summary
- As of today, INBX quarterly SG&A is $5.28 million, with the most recent change of -$1.15 million (-17.83%) on September 30, 2025.
- Over the past year, INBX quarterly SG&A has dropped by -$2.63 million (-33.24%).
- INBX quarterly SG&A is now -94.35% below its all-time high of $93.37 million, reached on June 30, 2024.
Performance
INBX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM SG&A:
-$647.02M-$155.09M(-31.53%)Summary
- As of today, INBX TTM SG&A is -$647.02 million, with the most recent change of -$155.09 million (-31.53%) on September 30, 2025.
- Over the past year, INBX TTM SG&A has dropped by -$758.27 million (-681.63%).
- INBX TTM SG&A is now -2881.41% below its all-time high of -$21.70 million.
Performance
INBX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Selling, General & Administrative Expenses Formula
SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development
INBX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +427.5% | -33.2% | -681.6% |
| 3Y3 Years | +935.3% | -1.3% | -3427.5% |
| 5Y5 Years | +1318.3% | +225.3% | -7245.5% |
INBX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +935.3% | -94.3% | at low | -97.1% | +71.8% |
| 5Y | 5-Year | at high | +1771.0% | -94.3% | +225.3% | -111.1% | +71.8% |
| All-Time | All-Time | at high | +4802.4% | -94.3% | +479.3% | -2881.4% | +71.8% |
INBX Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $5.28M(-17.8%) | $34.38M(-7.1%) |
| Jun 2025 | - | $6.42M(+6.6%) | $37.01M(-70.1%) |
| Mar 2025 | - | $6.02M(-63.8%) | $123.95M(-3.1%) |
| Dec 2024 | $127.91M(+427.5%) | $16.66M(+110.8%) | $127.91M(+15.0%) |
| Sep 2024 | - | $7.90M(-91.5%) | $111.24M(+7.6%) |
| Jun 2024 | - | $93.37M(+836.1%) | $103.34M(+499.5%) |
| Mar 2024 | - | $9.97M(+37.3%) | $17.24M(-29.2%) |
| Dec 2023 | $24.25M(+61.3%) | - | - |
| Jun 2023 | - | $7.26M(+13.5%) | $24.33M(+8.3%) |
| Mar 2023 | - | $6.40M(+20.2%) | $22.47M(+6.4%) |
| Dec 2022 | $15.04M(+21.7%) | $5.32M(-0.4%) | $21.12M(+8.6%) |
| Sep 2022 | - | $5.35M(-1.0%) | $19.45M(+14.7%) |
| Jun 2022 | - | $5.40M(+6.9%) | $16.95M(+17.7%) |
| Mar 2022 | - | $5.05M(+38.6%) | $14.40M(+16.5%) |
| Dec 2021 | $12.36M | $3.65M(+28.0%) | $12.36M(+13.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $2.85M(-0.2%) | $10.93M(+12.6%) |
| Jun 2021 | - | $2.85M(-5.2%) | $9.70M(+15.8%) |
| Mar 2021 | - | $3.01M(+35.8%) | $8.38M(+22.6%) |
| Dec 2020 | $6.84M(-24.2%) | $2.21M(+36.6%) | $6.84M(-24.5%) |
| Sep 2020 | - | $1.62M(+5.9%) | $9.05M(+1.6%) |
| Jun 2020 | - | $1.53M(+4.4%) | $8.91M(-1.2%) |
| Mar 2020 | - | $1.47M(-66.9%) | $9.02M(0.0%) |
| Dec 2019 | $9.02M(+93.8%) | $4.43M(+199.4%) | $9.02M(+96.7%) |
| Sep 2019 | - | $1.48M(-9.5%) | $4.58M(+47.7%) |
| Jun 2019 | - | $1.64M(+11.5%) | $3.10M(+26.3%) |
| Mar 2019 | - | $1.47M(+48.3%) | $2.46M(+29.3%) |
| Dec 2018 | $4.65M(+78.4%) | - | - |
| Jun 2018 | - | $989.00K(+8.6%) | $1.90M(+108.6%) |
| Mar 2018 | - | $911.00K | $911.00K |
| Dec 2017 | $2.61M | - | - |
FAQ
- What is Inhibrx Biosciences, Inc. annual SG&A?
- What is the all-time high annual SG&A for Inhibrx Biosciences, Inc.?
- What is Inhibrx Biosciences, Inc. annual SG&A year-on-year change?
- What is Inhibrx Biosciences, Inc. quarterly SG&A?
- What is the all-time high quarterly SG&A for Inhibrx Biosciences, Inc.?
- What is Inhibrx Biosciences, Inc. quarterly SG&A year-on-year change?
- What is Inhibrx Biosciences, Inc. TTM SG&A?
- What is the all-time high TTM SG&A for Inhibrx Biosciences, Inc.?
- What is Inhibrx Biosciences, Inc. TTM SG&A year-on-year change?
What is Inhibrx Biosciences, Inc. annual SG&A?
The current annual SG&A of INBX is $127.91M
What is the all-time high annual SG&A for Inhibrx Biosciences, Inc.?
Inhibrx Biosciences, Inc. all-time high annual SG&A is $127.91M
What is Inhibrx Biosciences, Inc. annual SG&A year-on-year change?
Over the past year, INBX annual SG&A has changed by +$103.66M (+427.49%)
What is Inhibrx Biosciences, Inc. quarterly SG&A?
The current quarterly SG&A of INBX is $5.28M
What is the all-time high quarterly SG&A for Inhibrx Biosciences, Inc.?
Inhibrx Biosciences, Inc. all-time high quarterly SG&A is $93.37M
What is Inhibrx Biosciences, Inc. quarterly SG&A year-on-year change?
Over the past year, INBX quarterly SG&A has changed by -$2.63M (-33.24%)
What is Inhibrx Biosciences, Inc. TTM SG&A?
The current TTM SG&A of INBX is -$647.02M
What is the all-time high TTM SG&A for Inhibrx Biosciences, Inc.?
Inhibrx Biosciences, Inc. all-time high TTM SG&A is -$21.70M
What is Inhibrx Biosciences, Inc. TTM SG&A year-on-year change?
Over the past year, INBX TTM SG&A has changed by -$758.27M (-681.63%)